Vaccines
13 articles RSS
Moderna-Merck Personalized mRNA Cancer Vaccine Sustains 49% Melanoma Risk Reduction at Five Years
Five-year KEYNOTE-942 trial data show Moderna and Merck's individualized neoantigen mRNA vaccine maintains a 49% reduction in melanoma recurrence or death.
4 min read4 sources